Ultragenyx to Present Pipeline Update at Analyst Day on Monday, October 16, 2023
05 Outubro 2023 - 9:00AM
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical
company focused on the development and commercialization of novel
therapies for rare and ultrarare genetic diseases, will host an
Analyst Day at 8:30 a.m. ET on Monday, October 16, 2023. Ultragenyx
leaders and external experts will provide an update on the
company’s development pipeline.
The agenda will include updates on UX143 for osteogenesis
imperfecta (OI), GTX-102 for Angelman syndrome (AS), and the
company’s gene therapy programs and platform. Two external
investigator panels will be featured:
Panel discussion on setrusumab (UX143) for the treatment
of osteogenesis imperfects (OI)
- Thomas Carpenter, M.D., Professor of Pediatrics (Endocrinology)
and of Orthopaedics and Rehabilitation, Yale School of Medicine and
Medical Director, Yale Center for Clinical Investigation's Hospital
Research Unit, and principal investigator for UX143 Phase 3
program
- Gary Gottesman, M.D., Professor of Pediatrics and Medicine,
Washington University School of Medicine in St. Louis, and
principal investigator for UX143 Phase 3 program
- Heather Byers, M.D., senior medical director at Ultragenyx
Panel discussion on GTX-102 for the treatment of
Angelman syndrome (AS)
- Elizabeth Berry-Kravis, M.D., Ph.D., Professor, Department of
Pediatrics, RUSH Medical College, and principal investigator for
GTX-102 Phase 1/2 study
- Kemi Olugemo, M.D., F.A.A.N., vice president of global clinical
development at Ultragenyx
Live Webcast
A live video webcast of the program will be available at
https://www.webcaster4.com/Webcast/Page/359/49192. An archived
version of the remarks will also be available through the
Ultragenyx website.
About Ultragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical company committed to bringing
novel products to patients for the treatment of serious rare and
ultrarare genetic diseases. The company has built a diverse
portfolio of approved therapies and product candidates aimed at
addressing diseases with high unmet medical need and clear biology
for treatment, for which there are typically no approved therapies
treating the underlying disease.
The company is led by a management team experienced in the
development and commercialization of rare disease therapeutics.
Ultragenyx’s strategy is predicated upon time- and cost-efficient
drug development, with the goal of delivering safe and effective
therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit
ultragenyx.com.
Forward-Looking Statements and Use of Digital
Media
Except for the historical information contained herein, the
matters set forth in this press release, including statements
related to Ultragenyx's expectations and projections regarding its
future operating results and financial performance, anticipated
cost or expense reductions, the timing, progress and plans for its
clinical programs and clinical studies, future regulatory
interactions, and the components and timing of regulatory
submissions are forward-looking statements within the meaning of
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Such forward-looking statements involve
substantial risks and uncertainties that could cause our clinical
development programs, collaboration with third parties, future
results, performance or achievements to differ significantly from
those expressed or implied by the forward-looking statements.
Ultragenyx undertakes no obligation to update or revise any
forward-looking statements. For a description of the risks and
uncertainties that could cause actual results to differ from those
expressed in these forward-looking statements, as well as risks
relating to the business of Ultragenyx in general, see Ultragenyx's
Quarterly Report on Form 10-Q filed with the Securities and
Exchange Commission on August 4, 2023 and its subsequent periodic
reports filed with the Securities and Exchange Commission.
In addition to its SEC filings, press releases and public
conference calls, Ultragenyx uses its investor relations website
and social media outlets to publish important information about the
company, including information that may be deemed material to
investors, and to comply with its disclosure obligations under
Regulation FD. Financial and other information about Ultragenyx is
routinely posted and is accessible on Ultragenyx’s investor
relations website (https://ir.ultragenyx.com/) and LinkedIn website
(https://www.linkedin.com/company/ultragenyx-pharmaceutical-inc-/)
Contacts – Ultragenyx Pharmaceutical, Inc.
InvestorsJoshua Higair@ultragenyx.com
MediaJeff Blake+1-415-612-7784media@ultragenyx.com
Ultragenyx Pharmaceutical (NASDAQ:RARE)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Ultragenyx Pharmaceutical (NASDAQ:RARE)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024